Vineet Laboratories
Vineet Laboratories Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Vineet Laboratories Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
Vineet Laboratories Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Vineet Laboratories Ltd, switchable between annual and quarterly views, consolidated or standalone.
Vineet Laboratories Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹64.92 Cr and reported EPS of ₹-20.47.
Vineet Laboratories segment analysis: revenue and profit mix.
Disclosed business segments at Vineet Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Vineet Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Vineet Laboratories Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Vineet Laboratories Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Vineet Laboratories Ltd's investment case rests on 4 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Pharmaceutical sector offers growth from increasing healthcare demand and advancements.
Diversification into new products or markets could capture emerging needs.
Strategic overhaul, including cost optimization, could unlock future growth potential.
Small market cap (424.35 Cr) makes it potential acquisition target.
What can break it.
Severe unprofitability with ROE -89.50% and ROCE -28.00%.
Quarterly sales plummeted -68.80%, indicating significant revenue contraction.
High debt-to-equity ratio of 2.74 poses substantial financial risk.
Promoter holding declined from 38.66% to 15.9%, signaling low confidence.
Consistent negative EPS -20.47 reflects inability to generate positive earnings.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 3.24. Balance sheet risk re-prices growth multiples fast.
Vineet Laboratories Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Vineet Laboratories Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Vineet Laboratories Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Vineet Laboratories Ltd — derived from the live tape, not yesterday's close.
Vineet Laboratories Ltd last traded at ₹38.55 with an intraday range of ₹36.51–₹39 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹38.55| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 44.51 | +5.96 | +15.46% |
| R3 | 42.02 | +3.47 | +9.00% |
| R2 | 40.51 | +1.96 | +5.08% |
| R1 | 39.53 | +0.98 | +2.54% |
| PIVOT | 38.02 | -0.53 | -1.37% |
| CURRENT | 38.55 | — | — |
| S1 | 32.06 | -6.49 | -16.84% |
| S2 | 34.55 | -4.00 | -10.38% |
| S3 | 35.53 | -3.02 | -7.83% |
| S4 | 37.04 | -1.51 | -3.92% |
VINEETLAB is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ~
Trading Inside opening range
Vineet Laboratories Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Vineet Laboratories Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Vineet Laboratories Ltd stood at 61.9% of traded volume, against a 20-day average of 57.8%.
Vineet Laboratories announcements: results, concalls, ratings, M&A.
Filings Vineet Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Vineet Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 81 documents below.
Resignation of Director/KMP/SMP
Vineet Laboratories Limited has informed the Exchange about Resignation of Director/KMP/SMP
- 29 Apr 2026Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarterView PDF
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
Vineet Laboratories Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Quarter ended 31 march FY 2026
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Vineet Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Trading Window
Vineet Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Vineet Laboratories insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Vineet Laboratories as reported to SEBI — buying and selling signals from the people who know the business best.
Vineet Laboratories insider activity below tracks 5 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| VENKATA RAMAGADDAM | Insider | 26 May 2025 | sell | −70.0 K | ₹22.47 L | ₹32.10 |
| Alluri Srinivasa Raju | Insider | 16 May 2025 | sell | −25.0 K | ₹8.08 L | ₹32.32 |
| Alluri Srinivasa Raju | Insider | 16 May 2025 | sell | −25.0 K | ₹8.08 L | ₹32.30 |
| Alluri Srinivasa Raju | Insider | 15 May 2025 | sell | −25.0 K | ₹7.66 L | ₹30.62 |
| Alluri Srinivasa Raju | Insider | 15 May 2025 | sell | −25.0 K | ₹7.64 L | ₹30.55 |
Vineet Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Vineet Laboratories has declared, sequenced by announce and record date.
Vineet Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Vineet Laboratories Ltd: business, sector, key facts.
What Vineet Laboratories Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Vineet Laboratories Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: VINEETLAB, BSE: 543298.
Vineet Laboratories Limited is an Indian company specializing in the research, development, manufacturing, and sales of active pharmaceutical ingredients (APIs) and fine chemicals. Their primary focus is on supplying crucial components for the pharmaceutical industry, contributing to the production of various medications.
A significant portion of Vineet Labs' business involves the production of intermediates for several key APIs. These intermediates are essential building blocks used in the synthesis of finished pharmaceutical products. Specific examples of APIs for which they supply intermediates include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. The company's ability to reliably produce these intermediates is vital to the supply chains of pharmaceutical manufacturers.
Beyond APIs, Vineet Laboratories also offers a diverse range of fine chemicals and reagents. These chemicals serve a variety of purposes in research and manufacturing settings, extending their reach beyond just pharmaceutical applications. The list of fine chemicals they provide is extensive and includes compounds such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, and various other specialized reagents. This diversification broadens their customer base and enhances their market position.
Established in 2007 and headquartered in Hyderabad, India, Vineet Laboratories has built its foundation on providing high-quality chemical products to both domestic and potentially international markets. Their success is likely linked to their expertise in chemical synthesis, quality control, and meeting the stringent demands of the pharmaceutical and research industries. The company’s commitment to research and development likely allows them to adapt to evolving market needs and introduce new products.
Questions investors ask about Vineet Laboratories Ltd (VINEETLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Vineet Laboratories Ltd (VINEETLAB)?
The current share price of Vineet Laboratories Ltd (VINEETLAB) is ₹38.55. Today, the stock has gained by ₹2.11 (5.79%), trading in a range of ₹36.51 to ₹39. The stock opened at ₹37.36 with a trading volume of 2,01,788 shares.
02Is Vineet Laboratories Ltd stock a good investment for long-term?
Vineet Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹64.92 crores, P/E ratio of 0.00, ROE of -66.72%, and ROCE of -28.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Vineet Laboratories Ltd stock?
The 52-week high price of Vineet Laboratories Ltd (VINEETLAB) is ₹49.99, while the 52-week low is ₹27.96. Currently trading at ₹38.55, the stock is 48.1% away from its 52-week low and 22.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Vineet Laboratories Ltd stock at the current price?
Whether to buy Vineet Laboratories Ltd stock at ₹38.55 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 4.37. Today's performance shows a gain of 5.79%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Vineet Laboratories Ltd and when is the next dividend?
Vineet Laboratories Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹38.55, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Vineet Laboratories Ltd?
Vineet Laboratories Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 4.37, ROE: -66.72%, ROCE: -28.00%, Dividend Yield: 0.00%, EPS: ₹-20.47, Book Value: ₹15.84, and Debt-to-Equity: 2.74. The company's market cap stands at ₹64.92 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Vineet Laboratories Ltd stock performing today in the market?
Vineet Laboratories Ltd stock opened at ₹37.36 and is currently trading at ₹38.55, showing a gain of ₹2.11 (5.79%). The intraday high is ₹39 and low is ₹36.51. The trading volume stands at 2,01,788 shares, indicating moderate market participation today.
08What is the P/E ratio of Vineet Laboratories Ltd and what does it indicate?
Vineet Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-20.47, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Vineet Laboratories Ltd (VINEETLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy